Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

 PMID:16461338  

Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity.

Troy Querec | Soumaya Bennouna | Sefik Alkan | Yasmina Laouar | Keith Gorden | Richard Flavell | Shizuo Akira | Rafi Ahmed | Bali Pulendran
The Journal of experimental medicine | 2006

The live attenuated yellow fever vaccine 17D (YF-17D) is one of the most effective vaccines available, with a 65-yr history of use in >400 million people globally. Despite this efficacy, there is presently no information about the immunological mechanisms by which YF-17D acts. Here, we present data that suggest that YF-17D activates multiple Toll-like receptors (TLRs) on dendritic cells (DCs) to elicit a broad spectrum of innate and adaptive immune responses. Specifically, YF-17D activates multiple DC subsets via TLRs 2, 7, 8, and 9 to elicit the proinflammatory cytokines interleukin (IL)-12p40, IL-6, and interferon-alpha. Interestingly, the resulting adaptive immune responses are characterized by a mixed T helper cell (Th)1/Th2 cytokine profile and antigen-specific CD8+ T cells. Furthermore, distinct TLRs appear to differentially control the Th1/Th2 balance; thus, whilst MyD88-deficient mice show a profound impairment of Th1 cytokines, TLR2-deficient mice show greatly enhanced Th1 and Tc1 responses to YF-17D. Together, these data enhance our understanding of the molecular mechanism of action of YF-17D, and highlight the potential of vaccination strategies that use combinations of different TLR ligands to stimulate polyvalent immune responses.

Pubmed ID: 16461338

Research resources used in this publication

None found

Antibodies used in this publication

None found

Associated grants

  • Agency: NIAID NIH HHS, United States
    Id: U19 AI057266
  • Agency: NIDDK NIH HHS, United States
    Id: R01 DK057665
  • Agency: NIAID NIH HHS, United States
    Id: R01 AI056499
  • Agency: NIAID NIH HHS, United States
    Id: R21 AI056957
  • Agency: NIAID NIH HHS, United States
    Id: R01 AI048638
  • Agency: NIAID NIH HHS, United States
    Id: U54 AI057157

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


C57BL/6J (tool)

RRID:IMSR_JAX:000664

Mus musculus with name C57BL/6J from IMSR.

View all literature mentions

SW480 (tool)

RRID:CVCL_0546

Cell line SW480 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

C3H/HeJ (tool)

RRID:IMSR_JAX:000659

Mus musculus with name C3H/HeJ from IMSR.

View all literature mentions

Abcam HeLa CCL2 KO (tool)

RRID:CVCL_B1MH

Cell line Abcam HeLa CCL2 KO is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

HEK293 (tool)

RRID:CVCL_0045

Cell line HEK293 is a Transformed cell line with a species of origin Homo sapiens (Human)

View all literature mentions

Vero (tool)

RRID:CVCL_0059

Cell line Vero is a Spontaneously immortalized cell line with a species of origin Chlorocebus sabaeus

View all literature mentions